800 million to 3 billion! IVD MEDICAL (01931) increases its ETH reserve quota, further upgrading the circulation infrastructure of medical innovative drugs.

On August 15, 2025, IVD MEDICAL (01931) announced a major announcement, proposing to apply for a maximum of 3 billion Hong Kong dollars for potential cryptocurrency purchases. This move aims to deepen its "Global Enhanced Ethereum (ETH) Treasury" strategy and accelerate the tokenization of medical innovation drug intellectual property (RWA) ecosystem (ivd.xyz exchange ecosystem) layout. According to the announcement, this matter constitutes a major acquisition under Chapter 14 of the Listing Rules of the Hong Kong Stock Exchange and requires approval by a special shareholders' meeting. Strategic upgrade: from 880 million to 3 billion, ETH reserve size leads the Hong Kong stock market The board of directors of IVD MEDICAL had previously approved the use of up to 880 million Hong Kong dollars to purchase Ethereum on the open market as a strategic reserve. As of August 8th, the company had completed the first batch of 5,190 ETH compliant purchases, with a total consideration of 149 million Hong Kong dollars, at an average cost of about 28,798 Hong Kong dollars per ETH (3,661 US dollars), funded by its own cash reserves. This transaction was completed through the licensed virtual asset exchange HashKey Exchange in Hong Kong, marking the substantial implementation of its "fixed investment-increasing holding-pledge earning-ecosystem feedback" closed-loop strategy. This new announcement will apply for an additional 3 billion Hong Kong dollars, if approved by shareholders, IVD MEDICAL will become a leading listed company in the Hong Kong stock market and even globally in terms of Ethereum reserve size. The company emphasized that the increase plan will strictly comply with the Hong Kong virtual asset regulatory framework and will be executed through compliant channels such as HashKey Group to ensure the security and liquidity of assets. Ecological synergy: ETH Treasury empowers medical RWA innovation IVD MEDICAL's cryptocurrency strategy is not an isolated layout, but deeply integrated with its core business - the tokenization of medical innovation drug assets (RWA). The company is transforming high-value medical innovation drug assets into divisible tradable digital certificates through its self-developed Web3 exchange ivd.xyz, building the "micro-strategy (MSTR) + Summit Therapeutics (SMMT)" in the medical RWA field. According to the announcement, Ethereum as the underlying infrastructure not only provides value anchoring for RWA but also feeds back the treasury size through pledge earnings. The company disclosed that its "seven-fold downside protection mechanism" and "three-tier income enhancement engine" have been fully launched, covering ATM financing, derivatives hedging, RWA price repurchase commitments, and other risk control measures to ensure shareholder interests are safeguarded in the volatile cryptocurrency market. Market response: Stock prices lead the medical sector, institutions are optimistic about the potential of "Ethereum micro-strategy" Since the announcement of the first batch of ETH purchases on August 8th, IVD MEDICAL's stock price has risen by over 91% in a month, with a market value exceeding 15 billion Hong Kong dollars, becoming the most watched "new species" in the Hong Kong stock medical sector. Market analysis points out that its "cryptocurrency treasury + medical RWA" dual-drive model is highly compatible with the valuation logic of leading companies in the Ethereum camp in the US stock market, such as Bitmine and SharpLink, but with more industrial synergies. Public information shows that the company has reached a strategic cooperation with HuaDa Win-Win Fund in the past and will continue to increase the asset thickness of the ivd.xyz exchange by acquiring high-quality innovative drug pipelines. Compliance first: strictly follow regulations, prioritize shareholder rights IVD MEDICAL reiterated in the announcement that all cryptocurrency transactions will be limited to regulated platforms and promised to seek independent approval at the special shareholders' meeting to ensure transparency of procedures. The company stated that if the 3 billion Hong Kong dollar application is approved, the authorization period will be 36 months, during which the board of directors can execute the purchase plan in stages according to market conditions. In the current trend of traditional medical companies exploring digital transformation, IVD MEDICAL's innovative model of "Ethereum treasury + medical RWA" has opened a new path for asset allocation and value reassessment in the industry. With the advancement of the 3 billion Hong Kong dollar strategy, whether it can become the "Hong Kong version of micro-strategy" is eagerly awaited by the market.